The experimental Alzheimer’s drug lecanemab slowed thinking declines among patients suffering the early stages of the disease in a new study, but safety concerns about brain swelling and brain bleeds remain. In the eagerly awaited trial findings, published Tuesday in the New England Journal of Medicine, researchers reported that lecanemab “reduced brain amyloid levels and… read on > read on >



















